Clinical efficacy of tezepelumab in pre-selected non-type 2 asthma patients

Allergy. 2024 Oct;79(10):2867-2870. doi: 10.1111/all.16237. Epub 2024 Jul 22.

Authors

T C Timothy Chin-See-Chong¹, J P M Johanna van der Valk^{1

2}, J A Janice Layhadi^{3

4}, M H Mohamed Shamji^{3

4}, J H Jasper Kappen^{1

3

4}

Affiliations

¹ Department of Pulmonary Diseases, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
² Department of Pulmonary Diseases, Erasmus Medical Centrum, Rotterdam, The Netherlands.
³ National Heart and Lung Institute, Imperial College London, London, UK.
⁴ Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.

PMID: 39034850
DOI: 10.1111/all.16237

No abstract available

Publication types

Letter

MeSH terms

Adult
Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized* / therapeutic use
Asthma* / drug therapy
Female
Humans
Male
Middle Aged
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Anti-Asthmatic Agents
tezepelumab